Windtree Therapeutics (WINT) Stock Price, News & Analysis

Company Overview

Windtree Therapeutics, Inc. is a clinical-stage biotechnology company developing innovative therapies for acute cardiovascular and pulmonary conditions. The company leverages its proprietary KL4 surfactant technology to address diseases marked by surfactant deficiency or dysfunction, with a primary focus on acute respiratory distress syndrome (ARDS) in adults and respiratory distress syndrome (RDS) in premature infants.

The company’s lead platform comprises synthetic peptide‐based surfactants designed to restore lung function by reducing surface tension in the alveoli. Windtree’s pipeline includes aerosolized and intratracheal formulations intended for rapid distribution in the lung, including programs that have advanced through preclinical studies and early-stage clinical trials. These programs aim to offer an alternative to animal-derived surfactants and to target patient populations with significant unmet medical needs.

Headquartered in Warrington, Pennsylvania, Windtree collaborates with academic research centers and clinical investigators across the United States and Europe to conduct its development programs. The company’s activities encompass formulation optimization, toxicology testing, and multi-site clinical evaluations, supported by partnerships that extend its reach into critical care and neonatal intensive care settings.

Under the leadership of President and CEO Michael Ott, Windtree maintains a management team with extensive experience in drug development, regulatory affairs and commercial strategy. The organization is committed to advancing its pipeline through regulatory interactions and clinical milestones in pursuit of therapies that can improve outcomes for patients with serious cardiopulmonary disorders.

Key Stats

• Today's Range: $0.14 to $0.19
• 50-Day Range: $0.06 to $0.60
• 52-Week Range: $0.06 to $60.00
• Volume: 1.24 million shs
• Average Volume: 4.98 million shs
• Market Capitalization: $4.61 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $350.00
• Consensus Rating: Hold

Windtree Therapeutics Stock Analysis - MarketRank™

Windtree Therapeutics scored higher than 39% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.0 / 5
• Analyst Rating: Hold

Consensus Rating

Windtree Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.

Upside Potential

Windtree Therapeutics has a consensus price target of $350.00, representing about 225,706.5% upside from its current price of $0.16.

Amount of Analyst Coverage

Windtree Therapeutics has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Windtree Therapeutics are expected to grow in the coming year, from ($5.66) to ($2.86) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Windtree Therapeutics is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Windtree Therapeutics is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Windtree Therapeutics has a P/B Ratio of 0.16. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.96% of the outstanding shares of Windtree Therapeutics have been sold short.

Short Interest Ratio / Days to Cover

Windtree Therapeutics has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Windtree Therapeutics has recently decreased by 15.14%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Windtree Therapeutics does not currently pay a dividend.

Dividend Growth

Windtree Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.96% of the outstanding shares of Windtree Therapeutics have been sold short.

Short Interest Ratio / Days to Cover

Windtree Therapeutics has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Windtree Therapeutics has recently decreased by 15.14%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

11 people have searched for WINT on MarketBeat in the last 30 days. This is an increase of 10% compared to the previous 30 days.

MarketBeat Follows

Only 2 people have added Windtree Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -71% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Windtree Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.15% of the stock of Windtree Therapeutics is held by insiders.

Percentage Held by Institutions

Only 29.33% of the stock of Windtree Therapeutics is held by institutions.

WINT Stock Analysis - Frequently Asked Questions

How have WINT shares performed this year?

Windtree Therapeutics' stock was trading at $17.4650 at the start of the year. Since then, WINT stock has decreased by 99.1% and is now trading at $0.1550.

How were Windtree Therapeutics' earnings last quarter?

Windtree Therapeutics, Inc. (NASDAQ:WINT) released its quarterly earnings data on Tuesday, August, 19th. The company reported ($3.06) earnings per share for the quarter, beating analysts' consensus estimates of ($99.00) by $95.94.

When did Windtree Therapeutics' stock split?

Windtree Therapeutics shares reverse split before market open on Friday, February 21st 2025.The 1-50 reverse split was announced on Tuesday, February 18th 2025. The number of shares owned by shareholders was adjusted after the market closes on Thursday, February 20th 2025. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

How do I buy shares of Windtree Therapeutics?

Shares of WINT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Windtree Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Windtree Therapeutics investors own include Plug Power (PLUG), Trevena (TRVN), SNDL (SNDL), AMC Entertainment (AMC), Sphere 3D (ANY), BioCardia (BCDA) and Sonnet BioTherapeutics (SONN).

Company Calendar

• Last Earnings: 8/19/2025
• Today: 10/10/2025
• Next Earnings (Estimated): 11/25/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:WINT
• CIK: 946486
• Web: www.windtreetx.com
• Phone: (215) 488-9300
• Fax: 215-488-9301
• Employees: 30
• Year Founded: 1992

Price Target and Rating

• Average Price Target for Windtree Therapeutics: $350.00
• High Price Target: $350.00
• Low Price Target: $350.00
• Potential Upside/Downside: +229,408.2%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): ($823.47)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$1.79 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -207.34%
• Return on Assets: -50.19%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.43
• Quick Ratio: 0.25

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.98 per share
• Price / Book: 0.16

Miscellaneous

• Outstanding Shares: 29,334,000
• Free Float: 3,656,000
• Market Cap: $4.47 million
• Optionable: Not Optionable
• Beta: 0.50